全文获取类型
收费全文 | 4923篇 |
免费 | 347篇 |
国内免费 | 4篇 |
专业分类
5274篇 |
出版年
2023年 | 17篇 |
2022年 | 26篇 |
2021年 | 63篇 |
2020年 | 23篇 |
2019年 | 25篇 |
2018年 | 52篇 |
2017年 | 40篇 |
2016年 | 84篇 |
2015年 | 126篇 |
2014年 | 148篇 |
2013年 | 256篇 |
2012年 | 260篇 |
2011年 | 245篇 |
2010年 | 176篇 |
2009年 | 186篇 |
2008年 | 261篇 |
2007年 | 284篇 |
2006年 | 299篇 |
2005年 | 289篇 |
2004年 | 294篇 |
2003年 | 282篇 |
2002年 | 277篇 |
2001年 | 144篇 |
2000年 | 147篇 |
1999年 | 122篇 |
1998年 | 55篇 |
1997年 | 51篇 |
1996年 | 49篇 |
1995年 | 58篇 |
1994年 | 63篇 |
1993年 | 53篇 |
1992年 | 81篇 |
1991年 | 75篇 |
1990年 | 51篇 |
1989年 | 56篇 |
1988年 | 56篇 |
1987年 | 45篇 |
1986年 | 64篇 |
1985年 | 40篇 |
1984年 | 22篇 |
1983年 | 36篇 |
1982年 | 30篇 |
1981年 | 20篇 |
1980年 | 22篇 |
1979年 | 31篇 |
1978年 | 19篇 |
1977年 | 19篇 |
1975年 | 21篇 |
1971年 | 13篇 |
1969年 | 20篇 |
排序方式: 共有5274条查询结果,搜索用时 15 毫秒
61.
62.
Studies on chemical synthesis of human cystatin A gene and its expression in Escherichia coli 总被引:1,自引:0,他引:1
A synthetic gene containing the coding sequence for the human cysteine proteinase inhibitor, cystatin A, was obtained by enzymatic assembly of 20 oligodeoxyribonucleotides which had been chemically synthesized by the solid phase phosphoramidite method. It was cloned into an Escherichia coli plasmid. The expression plasmid for cystatin A was constructed by introducing the synthetic gene downstream of the tac promoter of an E. coli plasmid which is a derivative of pKK223-3 with high copy number. The gene was expressed in E. coli JM109 without IPTG-induction. The expression of cystatin A was detected by SDS-polyacrylamide gel electrophoresis of the E. coli JM109 lysate, followed by immunoblotting using rabbit antiserum raised with human epidermal cystatin A and alkaline phosphatase-conjugated goat anti-rabbit IgG. The result showed that the molecular weight of the expression product is identical with that of the authentic protein and the antigenic properties are also the same. Furthermore, the expression product purified with a CM-papain Sepharose affinity column and FPLC system with a Mono-Q column showed the same inhibitory activity for various cysteine proteinases. Also, purified recombinant cystatin A was found to have identical amino acid composition, NH2-terminal amino acid sequence, and peptide-map on reverse phase HPLC with those of the authentic inhibitor. 相似文献
63.
64.
Umitsu M Morishita H Murata Y Udaka K Akutsu H Yagi T Ikegami T 《Journal of biomolecular NMR》2005,31(4):365-366
65.
Hitomi Yatsuki Ken Higashimoto Kosuke Jozaki Kayoko Koide Junichiro Okada Yoriko Watanabe Nobuhiko Okamoto Yoshinobu Tsuno Yoko Yoshida Kazutoshi Ueda Kenji Shimizu Hirofumi Ohashi Tsunehiro Mukai Hidenobu Soejima 《Genes & genomics.》2013,35(2):141-147
Beckwith-Wiedemann syndrome (BWS) is an imprinting-related human disease that is characterized by macrosomia, macroglossia, abdominal wall defects, and variable minor features. BWS is caused by several genetic/epigenetic alterations, such as loss of methylation at KvDMR1, gain of methylation at H19-DMR, paternal uniparental disomy of chromosome 11, CDKN1C mutations, and structural abnormalities of chromosome 11. CDKN1C is an imprinted gene with maternal preferential expression, encoding for a cyclin-dependent kinase (CDK) inhibitor. Mutations in CDKN1C are found in 40 % of familial BWS cases with dominant maternal transmission and in ~5 % of sporadic cases. In this study, we searched for CDKN1C mutations in 37 BWS cases that had no evidence for other alterations. We found five mutations—four novel and one known—from a total of six patients. Four were maternally inherited and one was a de novo mutation. Two frame-shift mutations and one nonsense mutation abolished the QT domain, containing a PCNA-binding domain and a nuclear localization signal. Two missense mutations occurred in the CDK inhibitory domain, diminishing its inhibitory function. The above-mentioned mutations were predicted by in silico analysis to lead to loss of function; therefore, we strongly suspect that such anomalies are causative in the etiology of BWS. 相似文献
66.
67.
68.
69.
Takahashi M Suzuki E Takeda R Oba S Nishimatsu H Kimura K Nagano T Nagai R Hirata Y 《American journal of physiology. Heart and circulatory physiology》2008,294(6):H2879-H2888
We examined whether ANG II and TNF-alpha cooperatively induce vascular inflammation using the expression of monocyte chemoattractant protein (MCP)-1 as a marker of vascular inflammation. ANG II and TNF-alpha stimulated MCP-1 expression in a synergistic manner in vascular smooth muscle cells. ANG II-induced MCP-1 expression was potently inhibited to a nonstimulated basal level by blockade of the p38-dependent pathway but only partially inhibited by blockade of the NF-kappaB-dependent pathway. In contrast, TNF-alpha-induced MCP-1 expression was potently suppressed by blockade of NF-kappaB activation but only modestly suppressed by blockade of p38 activation. ANG II- and TNF-alpha-induced activation of NF-kappaB- and p38-dependent pathways was partially inhibited by pharmacological inhibitors of ROS production. Furthermore, ANG II- and TNF-alpha-stimulated MCP-1 expression was partially suppressed by ROS inhibitors. We also examined whether endogenous ANG II and TNF-alpha cooperatively promote vascular inflammation in vivo using a wire injury model of the rat femoral artery. Blockade of both ANG II and TNF-alpha further suppressed neointimal formation, macrophage infiltration, and MCP-1 expression in an additive manner compared with blockade of ANG II or TNF-alpha alone. These results suggested that ANG II and TNF-alpha synergistically stimulate MCP-1 expression via the utilization of distinct intracellular signaling pathways (p38- and NFkappaB-dependent pathways) and that these pathways are activated in ROS-dependent and -independent manners. These results also suggest that ANG II and TNF-alpha cooperatively stimulate vascular inflammation in vivo as well as in vitro. 相似文献
70.